These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34972658)

  • 21. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches.
    Knoerl R; Smith EML; Han A; Doe A; Scott K; Berry DL
    Patient Educ Couns; 2019 Sep; 102(9):1636-1643. PubMed ID: 31003878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
    Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
    JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Course of Neuropathic Symptoms in Relation to Adjuvant Chemotherapy Among Elderly Patients With Stage III Colon Cancer: A Longitudinal Study.
    van Erning FN; Janssen-Heijnen MLG; Wegdam JA; Slooter GD; Wijsman JH; Vreugenhil A; Beijers TAJM; van de Poll-Franse LV; Lemmens VEPP
    Clin Colorectal Cancer; 2017 Sep; 16(3):195-203. PubMed ID: 27756521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
    Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ
    J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms.
    Tanay MAL; Armes J; Moss-Morris R; Rafferty AM; Robert G
    J Cancer Surviv; 2023 Feb; 17(1):254-277. PubMed ID: 33710510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
    Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
    Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.
    Kleckner IR; Jusko TA; Culakova E; Chung K; Kleckner AS; Asare M; Inglis JE; Loh KP; Peppone LJ; Miller J; Melnik M; Kasbari S; Ossip D; Mustian KM
    Breast Cancer Res Treat; 2021 Sep; 189(2):521-532. PubMed ID: 34191201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
    Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
    Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy.
    Stubblefield MD; McNeely ML; Alfano CM; Mayer DK
    Cancer; 2012 Apr; 118(8 Suppl):2250-60. PubMed ID: 22488699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial.
    Gewandter JS; Culakova E; Davis JN; Gada U; Guido JJ; Bearden JD; Burnette B; Shah D; Morrow GR; Mustian K; Sluka KA; Mohile N
    J Pain; 2024 May; 25(5):104431. PubMed ID: 37993030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study.
    Gewandter JS; Chaudari J; Ibegbu C; Kitt R; Serventi J; Burke J; Culakova E; Kolb N; Sluka KA; Tejani MA; Mohile NA
    Support Care Cancer; 2019 May; 27(5):1765-1774. PubMed ID: 30151681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
    Salgado TM; Quinn CS; Krumbach EK; Wenceslao I; Gonzalez M; Reed HL; Syverson JG; Etz RS; Vangipuram K; Barker MR; Henry NL; Farris KB; Hertz DL
    Support Care Cancer; 2020 Sep; 28(9):4163-4172. PubMed ID: 31897779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.
    Vichaya EG; Wang XS; Boyette-Davis JA; Mendoza TR; He Z; Thomas SK; Shah N; Williams LA; Cleeland CS; Dougherty PM
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1531-40. PubMed ID: 23543296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
    Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.